DBV Technologies Releases 2026 Mid-Year Financial Update and Progress Report

DBV Technologies announced its financial results for the second quarter and first half of 2026. The company reported cash reserves of $174.9 million, projected to support operations through the third quarter of 2027. Significant progress was noted toward regulatory submission for the VIASKIN® Peanut Patch, targeting children aged 4-7, with an anticipated submission to the FDA in Q3 2026.

Operational highlights included advancements in clinical trials, notably the closing of recruitment for the COMFORT Toddlers study and the initiation of the THRIVE study. DBV continues strategic investments in launch preparedness, despite a net loss of $98.0 million for the half-year, reflecting ongoing research and commercial readiness activities.

The company's integration into key European stock indices demonstrates its enhanced visibility within the investment community. DBV's engagement with scientific communities remains robust, aiming to further the understanding and application of its VIASKIN® technology.